Major Leadership Transition at Aquestive Therapeutics: Chief Legal Officer and Chief Compliance Officer Roles Change Hands

Key Developments:

• Lori J. Braender to Step Down as Chief Legal Officer and Chief Compliance Officer; Will Remain as Corporate Secretary in a Non-Executive Role
• Thomas A. Zalewski, Former Partner and Chair of Healthcare & Life Sciences at Day Pitney LLP, Appointed as Successor
• Significant Severance and Compensation Arrangements for Ms. Braender
• Inducement Equity Grants Announced for Mr. Zalewski

Detailed Summary

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company specializing in innovative drug delivery technologies, has announced a major change in its senior executive team that could have significant implications for the company’s strategic direction and share value.

1. Executive Transition and Succession

On March 16, 2026, the company disclosed that Lori J. Braender, who has served as Chief Legal Officer (CLO), Chief Compliance Officer (CCO), and Corporate Secretary for nearly eight years, will be stepping down from her CLO and CCO roles effective April 2, 2026. She will no longer serve as an executive officer of the company. However, Ms. Braender will remain at Aquestive in a non-executive capacity as Corporate Secretary, focusing on transition duties through May 7, 2026, and continuing as Corporate Secretary thereafter.

Shareholders should note the detailed severance and compensation package agreed with Ms. Braender:

• She will receive her current base salary through May 7, 2026, for transition services.
• She will receive monthly severance payments for 12 months after May 7, 2026, equal to 1/12 of her pre-termination base salary plus target annual bonus.
• She will have continued coverage under the company’s health and life insurance plans for 12 months post-termination, on the same terms as other executives.
• All unvested stock options, RSUs, SARs, restricted stock, and other equity-based compensation will fully vest on May 7, 2026. These awards will remain exercisable for at least five years or until the end of their stated term. For equity awards with performance conditions ending after May 7, 2026, the performance will be deemed achieved at target.
• She also retains severance protections under her prior employment agreement, including in the event of a change in control.
• Her new compensation as Corporate Secretary is set at \$15,000 per month, with eligibility for senior executive benefit plans.

These extensive arrangements represent a significant financial commitment by the company and may impact future compensation expenses and cash flows.

2. Appointment of Thomas A. Zalewski

Thomas A. Zalewski will take over as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026. Mr. Zalewski brings a robust background, having served as a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP. His expertise in strategic, commercial, and regulatory matters is expected to bolster Aquestive’s leadership team as the company advances key programs and navigates regulatory processes.

3. Inducement Equity Grants for Incoming Executive

To attract Mr. Zalewski, the company’s Compensation Committee has approved substantial inducement equity awards, which could have a dilutive effect and thus be material for shareholders:

• 100,000 Restricted Stock Units (RSUs) and 75,000 non-qualified stock options, both granted outside the company’s 2018 Equity Incentive Plan under the Nasdaq employment inducement rule.
• These awards will vest 25% on each of the first and second anniversaries of the grant date, and 50% on the third anniversary, subject to continued employment.
• The options have a 10-year term and an exercise price set at the closing price on May 8, 2026 (the scheduled grant date).

Such equity grants are structured to align the new executive’s interests with shareholders and incentivize long-term value creation, but may also impact share count and potential dilution.

4. Potential Shareholder Impact and Price Sensitivity

• Leadership Transition: The replacement of a long-tenured legal and compliance executive with a new appointee is a significant governance event. Investors may interpret this as an inflection point for corporate strategy and risk management posture.
• Financial Commitment: The severance, accelerated vesting, and ongoing compensation agreements mean increased near-term expenses, which could affect profitability metrics.
• Equity Dilution: The inducement grants to Mr. Zalewski, especially as they are made outside the existing equity plan, may raise concerns about share dilution and long-term shareholder value.
• Strategic Potential: Mr. Zalewski’s regulatory and strategic experience could prove valuable as Aquestive advances its product pipeline, including Anaphylm™ (oral epinephrine) and AQST-108. Progress in these programs could be price-sensitive and affect the stock’s performance.

5. Forward-Looking Statements and Risks

The company has reminded investors that forward-looking statements about product pipeline advancement, regulatory filings, and market opportunities are subject to risks, including regulatory delays, clinical trial outcomes, and other uncertainties affecting the pharmaceutical sector.

Conclusion

This leadership change, combined with the accompanying compensation and equity arrangements, is a material development for Aquestive Therapeutics and should be closely monitored by investors. The company’s ability to execute its pipeline strategy and manage executive transitions will be key factors in future share performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks, and actual outcomes may differ materially. Investors should review official filings and consult with financial advisors before making investment decisions.

View Aquestive Therapeutics, Inc. Historical chart here